Bloomios

Bloomios Equity Ratio

The Equity Ratio of Bloomios (BLMS) as of Oct 27, 2026 is -5.08 %. In the previous year, Equity Ratio was -39.17 % — a change of -87.03% (higher).

Equity Ratio

-5.08 %

YoY

-87.03%

Last updated:

Equity Ratio of Bloomios is 2022 -5.08 % . Equity Ratio of Bloomios was 2021 -39.17 % . It decreases by -87.03% higher compared to the previous year.

The Bloomios Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
-45,250.81 USD
Jan 1, 2020
-39.58 USD
Jan 1, 2021
-39.17 USD
Jan 1, 2022
-5.08 USD
The Bloomios Equity Ratio history
YEAREquity RatioYoY
-5.08 %-87.03%
-39.17 %-1.04%
-39.58 %-99.91%
-45,250.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bloomios Stock analysis

What does Bloomios do? Bloomios, Inc. generates revenue through the wholesale distribution of U.S. hemp-derived supplements and cosmetic products. The company manufactures and distributes hemp-infused edibles, pet edibles, tinctures, shots, topicals, smokable hemp, and other products across seven categories including edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. BPL, a subsidiary of Bloomios, focuses on manufacturing and distributing hemp-derived nootropic and nutraceutical products to wholesalers and retailers. Bloomios provides private-label and white-label services with over 80 customizable products and custom formulation and manufacturing support for its customers. The company's primary customers are wholesalers and retailers who purchase its hemp-derived products for resale. Bloomios offers a comprehensive suite of services including custom formulation, order fulfillment, and brand development to support its clients. Its product portfolio spans multiple categories such as human edibles, pet edibles, liquid consumables, topicals, and smokable hemp, catering to both consumer and pet markets. Bloomios leverages its subsidiary BPL to expand its product offerings in the hemp-derived nootropic and nutraceutical sectors. The company's focus on customizable solutions allows it to serve a diverse range of clients seeking private-label and white-label hemp products. Through its wholesale distribution channels, Bloomios targets businesses looking to sell hemp-based supplements and cosmetics under their own brand names. Bloomios is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bloomios stock

Equity Ratio of Bloomios is -5.08 % in 2022.

Equity Ratio of Bloomios changed from -39.17 % to -5.08 %, representing a -87.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Bloomios since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Bloomios with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bloomios

All Key Metrics — Bloomios